Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Harnessing NK-cells to treat AML

Paola Minetto, MD, PhD, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, comments on harnessing natural killer (NK)-cells for the treatment of acute myeloid leukemia (AML). One possible approach, which Dr Minetto and colleagues are exploring in an ongoing trial, is the infusion of alloreactive NK-cells from a haploidentical donor into patients with AML who are not eligible for allogeneic stem cell transplantation (alloSCT). CAR-NK cells also present a potential avenue for the treatment of this hematological malignancy. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.